Debra Sarasohn

1.7k total citations
36 papers, 1.2k citations indexed

About

Debra Sarasohn is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Debra Sarasohn has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Reproductive Medicine, 11 papers in Oncology and 9 papers in Surgery. Recurrent topics in Debra Sarasohn's work include Ovarian cancer diagnosis and treatment (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). Debra Sarasohn is often cited by papers focused on Ovarian cancer diagnosis and treatment (13 papers), Lymphoma Diagnosis and Treatment (9 papers) and Intraperitoneal and Appendiceal Malignancies (7 papers). Debra Sarasohn collaborates with scholars based in United States, Switzerland and Ireland. Debra Sarasohn's co-authors include Nadeem R. Abu‐Rustum, S. Dennis, Hedvig Hricak, Yukio Sonoda, Craig H. Moskowitz, Paul A. Hamlin, Andrew D. Zelenetz, Svetlana Mironov, Owen A. O’Connor and Revathy B. Iyer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Radiology.

In The Last Decade

Debra Sarasohn

36 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Debra Sarasohn United States	19	447	363	317	273	265	36	1.2k
James J. Burke United States	17	674 1.5×	267 0.7×	101 0.3×	984 3.6×	242 0.9×	27	1.6k
Helen A. Bean Canada	13	394 0.9×	325 0.9×	286 0.9×	343 1.3×	258 1.0×	23	1.1k
Nick Reed United Kingdom	17	540 1.2×	289 0.8×	95 0.3×	430 1.6×	836 3.2×	37	1.6k
Roger A. Potish United States	22	360 0.8×	378 1.0×	100 0.3×	706 2.6×	243 0.9×	64	1.3k
F. A. Beale Canada	16	349 0.8×	499 1.4×	148 0.5×	295 1.1×	263 1.0×	18	1.2k
Vanessa Samouëlian Canada	17	478 1.1×	472 1.3×	176 0.6×	910 3.3×	744 2.8×	75	1.7k
M. Lahousen Austria	22	1.2k 2.6×	665 1.8×	247 0.8×	1.0k 3.8×	348 1.3×	82	1.9k
G Farrer-Brown United States	16	293 0.7×	193 0.5×	506 1.6×	274 1.0×	250 0.9×	40	1.3k
J. F. Pringle Canada	18	355 0.8×	363 1.0×	89 0.3×	365 1.3×	480 1.8×	22	1.3k
Kevin Norwood United States	22	153 0.3×	779 2.1×	363 1.1×	222 0.8×	1.3k 4.9×	38	1.8k

Countries citing papers authored by Debra Sarasohn

Since Specialization

Citations

This map shows the geographic impact of Debra Sarasohn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra Sarasohn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra Sarasohn more than expected).

Fields of papers citing papers by Debra Sarasohn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra Sarasohn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra Sarasohn. The network helps show where Debra Sarasohn may publish in the future.

Co-authorship network of co-authors of Debra Sarasohn

This figure shows the co-authorship network connecting the top 25 collaborators of Debra Sarasohn. A scholar is included among the top collaborators of Debra Sarasohn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra Sarasohn. Debra Sarasohn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lumish, Melissa, M. Herman Chui, Qin Zhou, et al.. (2024). A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). Gynecologic Oncology. 182. 75–81. 7 indexed citations

Manning‐Geist, Beryl, Sacha Gnjatic, Carol Aghajanian, et al.. (2023). Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers. 15(5). 1458–1458. 12 indexed citations

Filippova, Olga T., Renee A. Cowan, Yulia Lakhman, et al.. (2020). A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. Gynecologic Oncology. 158(3). 608–613. 24 indexed citations

Cadoo, Karen A., Rachel N. Grisham, Roisin E. O’Cearbhaill, et al.. (2020). A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecologic Oncology. 157(1). 214–221. 3 indexed citations

Gluskin, Jill S., et al.. (2020). Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: A retrospective observational study. Clinical Imaging. 71. 29–33. 3 indexed citations

Soff, Gerald A., Jodi V. Mones, Sean M. Devlin, et al.. (2019). Rivaroxaban treatment of cancer‐associated venous thromboembolism: Memorial Sloan Kettering Cancer Center institutional experience. Research and Practice in Thrombosis and Haemostasis. 3(3). 349–356. 22 indexed citations

Kumar, Amanika, Shannon P. Sheedy, R.S. Suidan, et al.. (2019). Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease. Gynecologic Oncology. 154(1). 72–76. 18 indexed citations

O’Cearbhaill, Roisin E., Sacha Gnjatic, Carol Aghajanian, et al.. (2018). A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.. Journal of Clinical Oncology. 36(15_suppl). 5553–5553. 6 indexed citations

Suidan, R.S., Pedro T. Ramírez, Debra Sarasohn, et al.. (2017). A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. Gynecologic Oncology. 145(1). 27–31. 95 indexed citations

10.

Cowan, Renee A., Ginger J. Gardner, Douglas A. Levine, et al.. (2015). Is It Time to Centralize Ovarian Cancer Care in the United States?. Annals of Surgical Oncology. 23(3). 989–993. 40 indexed citations

11.

Suidan, R.S., Pedro T. Ramírez, Debra Sarasohn, et al.. (2014). A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecologic Oncology. 134(3). 455–461. 168 indexed citations

12.

Lakhman, Yulia, Oğuz Akın, Kay J. Park, et al.. (2013). Stage IB1 Cervical Cancer: Role of Preoperative MR Imaging in Selection of Patients for Fertility-Sparing Radical Trachelectomy. Radiology. 269(1). 149–158. 65 indexed citations

13.

Gerecitano, John F., Carol S. Portlock, Paul A. Hamlin, et al.. (2011). Phase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin Lymphoma. Clinical Cancer Research. 17(8). 2493–2501. 21 indexed citations

14.

Dennis, S., Joyce N. Barlin, Pedro T. Ramírez, et al.. (2010). Follow-Up Study of the Correlation Between Postoperative Computed Tomographic Scan and Primary Surgeon Assessment in Patients With Advanced Ovarian, Tubal, or Peritoneal Carcinoma Reported to Have Undergone Primary Surgical Cytoreduction to Residual Disease of 1 cm or Smaller. International Journal of Gynecological Cancer. 20(3). 353–357. 16 indexed citations

15.

O’Connor, Owen A., Steven M. Horwitz, Paul A. Hamlin, et al.. (2009). Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies. Journal of Clinical Oncology. 27(26). 4357–4364. 131 indexed citations

16.

Gerecitano, John F., Carol S. Portlock, Craig H. Moskowitz, et al.. (2009). Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology. 146(6). 652–655. 39 indexed citations

17.

Gerecitano, John F., Carol S. Portlock, Paul A. Hamlin, et al.. (2009). Rituximab, Cyclophosphamide, Bortezomib and Prednisone (R-CBorP): Final Results of a Phase I Trial Evaluating Two Dosing Schedules and the Safety of Overlapping Pegfilgrastim in Patients with Relapsed/Refractory Indolent and Mantle Cell Lymphomas.. Blood. 114(22). 3708–3708. 4 indexed citations

18.

O’Connor, Owen A., Paul A. Hamlin, Carol S. Portlock, et al.. (2007). Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma. British Journal of Haematology. 139(3). 425–428. 68 indexed citations

19.

Gollub, Marc J., Hong Ren, Debra Sarasohn, & Timothy Akhurst. (2007). Limitations of CT During PET/CT. Journal of Nuclear Medicine. 48(10). 1583–1591. 35 indexed citations

20.

Hamlin, Paul A., Ellen Neylon, Craig H. Moskowitz, et al.. (2005). Pralatrexate (10-Propargyl-10-Deazaaminopterin (PRX)), a Novel Antifolate, Effects Durable Complete Remissions (CR) in Patients with a Diversity of Drug Resistant T-Cell Lymphomas with Minimal Toxicity.. Blood. 106(11). 2678–2678. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact